维普期刊资源整合服务平台（V6.5）

24篇 您的检索式：作者名="Aulinger BA"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Targeting beta-cell mass in type 2 diabetes:promise and limitations of new drugs based on incretins显示文摘	Salehi M Aulinger BA D'Alessio DA	2008	Endocr Rev2008，29，：	1
2	Targeting beta-cell mass in type 2 diabetes:promise and limitations of new drugs based on incretins显示文摘	Salehi M Aulinger BA D'Alessio DA	2008	Endocr Rev2008，29，3：	1
3	Targeting beta-cell massin type 2 diabetes : promise and limitations of new drugs based onincretins显示文摘	Salehi M Aulinger BA DrAlessio DA	2008	Endocr Rev2008，29，3：	1
4	Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins 显示文摘	Lehi M Aulinger BA D'Alessio DA	2008	Endocr Rev2008，29，3：	1
5	Targeting \|3 -cell massin type 2 diabetes : promise and limitations of uew drugsbased on incretins显示文摘	Salehi M Aulinger BA D'Alessio DA	2008	Endocr Rev2008，29，3：	1
6	Targeting beta - cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins 显示文摘	Salehi M Aulinger BA D' Alessio DA	2008	Endocr Rev2008，29，3：	1
7	Targeting β-cell mass in type diabetes:promise and limitations of new drugs based on incretins显示文摘	Salehi M Aulinger BA D'Alessio DA		0，，03：	1
8	Targetingβ-cell mass in type 2 diabetes:promise and limitations of new drugs based on incretins显示文摘	Salehi M Aulinger BA D’Alessio DA	2008	Endocr Rev2008，29，2：	1
9	Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines 显示文摘	Aulinger BA Roehrl MH Mekalanos JJ	2005	Infect Immun2005，73，6：	1
10	Targeting beta-cell mass in type 2 diabetes : promise and limitations of new drugs based on in- cretins显示文摘	Salehi M Aulinger BA D'Alessio DA	2008	Endocr Rev2008，29，3：	1
11	Targeting p-cell mass intype 2 diabetes : promise and limitations of new drugs based onincretins 显示文摘	Salehi M Aulinger BA D Alessio DA	2008	Endocr Rev2008，29，3：	1
12	Targeting β - cell mass in type 2 diabetes : promise and limitations of new drugs based on incretins 显示文摘	Salehi M Aulinger BA D' Alessio DA	2005	Endocr Rev2005，29，：	1
13	Targeting betacell mass in type 2 diabetes:promise and limitations of new drugs based on incretins显示文摘	Salehi M Aulinger BA DAlessio DA		0，，03：	1
14	Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and 1vle of dipeptidyl peptidase-4显示文摘	Jessen L Aulinger BA Hassel JL	2012	Endncfinology2012，153，12：	1
15	Targeting B cell mass in type 2 diabetes : promise and limetations of new drugs based on incretins 显示文摘	Salehi M Aulinger BA Dlessio DA	2008	Endocr Rev2008，29，3：	1
16	Targeting beta-cell mase in type 2 diabetes:promise and limitations of new drags based on incretins显示文摘	Salehi M Aulinger BA d' Alessio DA		0，，：	1
17	Targeting 8-cell mass in type 2 diabetes: promise and limitations of new drugs bas- ed on incretins 显示文摘	Salehi M Aulinger BA DAlessio DA	2008	Endocr Rev2008，29，3：	1
18	Targeting betacell mass in type 2 diabetes:promise and limitations of new drugs based on incretins显示文摘	Salehi M Aulinger BA DAlesaio DA		0，，03：	1
19	Targeting beta-cell mass in type 2 diabetes:promise and limitations of new drugs based on incretins显示文摘	Salehi M Aulinger BA D’alessio DA	2008	Endocr Rev2008，29，3：	1
20	Targeting beta-cell mass in type 2 diabetes:promise and limitations of new drugs based on incretins显示文摘	Salehi M Aulinger BA D'Alessio DA	2008	Endocr Rev2008，29，3：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示